Publication

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Publications associées (29)

Nanotechnology enabled modulation of T cell immunity for cancer treatment

Recent breakthroughs in cancer immunotherapy, exemplified by immune checkpoint blockade and CAR T cell therapy, have achieved remarkable clinical success. However, the majority of cancer patients fail to respond to immunotherapy or suffer from relapse. Nan ...

EPFL2023

Engineering Innate and Adaptive Immunity for Enhanced Cancer Immunotherapy

Min Gao

Cancer immunotherapy has become an attractive strategy among different therapeutic modalities over the past few years and has showed great success in the clinic. However, there are many outstanding challenges hindering the current immunotherapies. In my Ph ...

EPFL2023

Metabolic dependencies of metastasis-initiating cells in female breast cancer

Jörg Hülsken, Albert Santamaria Martinez, Pierre Vincent Dessen, Laurent Nam Ky Beziaud, Candice Megan T Young, Angela Madurga Alonso

Understanding the mechanisms that enable cancer cells to metastasize is essential in preventing cancer progression. Here we examine the metabolic adaptations of metastasis-initiating cells (MICs) in female breast cancer and how those shape their metastatic ...

Nature Portfolio2023

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma

Cathrin Brisken, Laura Battista, Georgios Sflomos

Simple Summary Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and is often detected at an advanced stage. Up to 30% of ILC cases relapse and present a challenge for treatment. Unfortunately, there are few mod ...

MDPI2023

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Agnieszka Alicja Chryplewicz

Glioblastoma (GBM) is the most frequent and highly malignant form of brain cancer. New therapeutic regimens are urgently needed as GBM patients present with a minimal response to currently-approved therapies. The goal of this project is to identify new the ...

EPFL2023

Tumor dormancy: EMT beyond invasion and metastasis

Cathrin Brisken, Patrik Aouad, Hazel Margaret Quinn

More than two-thirds of cancer-related deaths are attributable to metastases. In some tumor types metastasis can occur up to 20 years after diagnosis and successful treatment of the primary tumor, a phenomenon termed late recurrence. Metastases arise from ...

WILEY2023

Development of next-generation microfluidic systems for enhanced, faster, and cost-effective immunoassays for tissue diagnostics - Ac electrothermal flow & Acoustofluidics

Muaz Salama Abdelmonem Draz

The application of microfluidics in the field of surface-based assays and more specifically, the spatial molecular profiling of tumor tissues has gained a lot of interest, especially with the increased interest in personalized medicine and targeted therapy ...

EPFL2023

Investigating the effect of inflammation on the progression of B-cell lymphoma dissemination in the sentinel lymph node

Daniel Molina Romero

Lymphomas are a group of heterogeneous blood cancers that arise from lymphocytes. The two primary clinical classifications of lymphomas are Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). In particular, B-cell lymphoma refers to the malignancies ...

EPFL2023

Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis

Bart Deplancke, Jorieke Weiden, Guido Van Mierlo

Adoptive T cell therapyhas successfully been implementedfor thetreatment of cancer. Nevertheless, ex vivo expansion of T cells byartificial antigen-presenting cells (aAPCs) remains cumbersome andcan compromise T cell functionality, thereby limiting their t ...

AMER CHEMICAL SOC2023